Last update July 25, 2022
Very Low Risk
Peripheral vasodilator. Indicated in the treatment of arterial hypertension and heart failure. Oral administration every 6 to 12 hours. Intravenous use in hypertensive emergencies.
It is excreted into breast milk in clinically non-significant amount (Lamont 1986, Franke 1986, Liedholm 1982). No problem was observed in infants whose mothers were on this medication. (AEMPS 2012)
Plasma levels in those infants were undetectable or very low, between 15 and 30 times lower than those observed in neonates after therapeutic use. (Lamont 1986)
Several medical societies, experts and expert consensus, consider the use of this medication safe during breastfeeding (Kearney 2018, Anderson 2018, Malachias 2016, Ghanem 2008). The American Academy of Pediatrics rates it as a medication usually compatible with breastfeeding (AAP 2001). WHO List of Essential Medicines 2002: compatible with breastfeeding. (WHO 2002)
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM